Cosmetic use of bifidobacterium species lysate for the treatment of dryness

ABSTRACT

Cosmetic use of an effective amount of a lysate of at least one microorganism of the genus  Bifidobacterium  species and/or one of its fractions in treating and/or preventing dryness and/or associated disorders of a keratinous substance.

This non provisional application claims the benefit of FrenchApplication No. 07 57348 filed on Sep. 4, 2007 and U.S. ProvisionalApplication No. 60/973,541 filed on Sep. 19, 2007.

The present disclosure mainly concerns at providing a novel activeprinciple for preventing and/or treating dryness of keratinoussubstances and in particular skin described as dry.

BACKGROUND

It is known that an increase in cutaneous dryness is often observed withage; however, such cutaneous dryness states may also occur in youngsubjects. This is because the cutaneous dryness state is a physiologicalstate which may be present in young subjects without any pathologicalcause, at least apparent pathological cause. The origin of this drynessmay be constitutional or acquired. Thus, many external factors canresult in drying of the skin or can aggravate the state of the skinwhich is already dry. Mention may be made, among these factors, ofdifficult climatic conditions, solar radiation, or exposure to certainchemical or therapeutic agents.

Dry skin is often associated physiologically with a fall in the level ofcutaneous hydration and with a detrimental change in the barrierfunction, measured by the imperceptible water loss. It is in particularcharacterized sensorially by a feeling of skin tightness and/or tension.For obvious reasons, these manifestations are sources of discomfort,indeed even of pain.

SUMMARY

There thus remains a need to have available novel active principlescapable of exerting a beneficial cosmetic or therapeutic effect on theepidermis or keratinous substances in general which are described asdry. Within the meaning of the disclosure, the term “epidermis” isintended to denote both the skin and the scalp.

Unexpectedly, the Inventors have found that some probioticmicroorganisms can prove to be particularly effective in the preventionand/or treatment of dry skin, with the proviso that they are employed inthe form of a lysate.

Consequently, according to a first aspect, a subject-matter of thedisclosure is the cosmetic use of an effective amount of a lysate of atleast one microorganism of the genus Bifidobacterium species and/or oneof its fractions for treating and/or preventing dryness and/orassociated disorders of a keratinous substance, in particular dryepidermides, such as the skin or scalp.

According to another of its aspects, the present disclosure concerns theuse of an effective amount of a lysate of at least one microorganism ofthe genus Bifidobacterium species and/or one of its fractions in thepreparation of a composition intended to treat and/or prevent drynessand/or associated disorders of a keratinous substance.

In particular, such a composition proves to be effective in treatingichthyoses, psoriasis, hyperkeratoses, topical dermatitides and drydandruff states of the scalp.

The present disclosure relates, according to another of its aspects, tothe cosmetic use of an effective amount of a lysate of at least onemicroorganism of the genus Bifidobacterium species and/or one of itsfractions in treating and/or preventing a dry dandruff state of thescalp, and more particularly dry dandruffs.

According to another of its aspect, the present disclosure concerns theuse of an effective amount of a lysate of at least one microorganism ofthe genus Bifidobacterium species and/or one of its fractions in thepreparation of a composition intended to treat and/or prevent a drydandruff state of the scalp.

Within the meaning of the present disclosure, the term “to prevent”means to reduce the risk of appearance of the phenomenon concerned.

According to another of its aspects, a subject-matter of the disclosureis a method, in particular a cosmetic method, for treating and/orpreventing dryness and/or associated disorders of a keratinoussubstance, in particular dry epidermides, such as the skin or scalp, ina subject, comprising at least one step of administration to the saidsubject of at least an effective amount of a lysate of at least onemicroorganism of the genus Bifidobacterium species and/or one of itsfractions.

According to another of its aspects, a subject-matter of the presentdisclosure is a cosmetic and/or dermatological composition, of use inparticular for preventing and/or treating dry keratinous substances, inparticular dry epidermides, such as the skin or scalp, comprising, in aphysiologically acceptable carrier, at least an effective amount of alysate of at least one microorganism of the genus Bifidobacteriumspecies and/or one of its fractions, in combination with an effectiveamount of at least one additional microorganism, in particular aprobiotic microorganism, distinct from said lysate.

Within the meaning of the disclosure, the expression “distinct from saidlysate” means that it is possible to distinguish, within thecomposition, either two different microorganisms or two different formsof the same microorganism. Thus, when the additional microorganism is ofthe genus Bifidobacterium species and corresponds to the same species asthat representing the lysate required according to the disclosure, thisadditional microorganism is then present in a form other than a lysate.

According to another of its aspects, the present disclosure concerns acosmetic and/or dermatological composition, of use in particular forpreventing and/or treating dry keratinous substances, in particular dryepidermides, such as the skin or scalp, comprising, in a physiologicallyacceptable carrier, at least an effective amount of a lysate of at leastone microorganism of the genus Bifidobacterium species and/or one of itsfractions, in combination with an effective amount of at least onemoisturizing active principle in particular as described below.

Urea and its derivatives are very particularly suitable as such.

According to an alternative embodiment of the disclosure, the lysateaccording to the disclosure can be administered by the oral route.

According to another alternative embodiment of the disclosure, thelysate according to the disclosure can be administered by the topicalroute.

As specified below, the compositions comprising it are formulated inorder to be compatible with the method of administration selected.

The term “effective amount” is understood to mean, within the meaning ofthe present disclosure, an amount sufficient to produce the expectedeffect.

DETAILED DESCRIPTION OF EMBODIMENTS

Dry Skin

As indicated above, dry skin is essentially expressed by a feeling oftightness and/or tension. The skin is also rough to the touch andappears covered with squamae. When the skin is slightly dry, thesesquamae are profuse but not very visible to the naked eye. They becomesless numerous but increasingly visible to the naked eye when thisdisorder worsens.

In the scalp, the formation of such dry squamae or dandruff issymptomatic of a dry dandruff state.

With respect to the scalp, the dry dandruff states are chronic,frequent, recurring and socially disabling states. Stress and the winterperiod reinforce these states in the majority of the individuals. Theintegrity and homeostasis of the scalp are regulated by an assembly ofparameters including sebum secretion and the intra-individualsensitivity.

Thus, during dandruff states of the scalp, the cutaneous barrier, itsintegrity and its ecological flora are unbalanced.

The skin of the scalp is irritated, and pruriginous, fragile, lesshydrated and develops significant desquamation which is reflected a drydandruff state.

A dry dandruff state is different from a greasy dandruff state.

The former is reflected in particular by the presence of white or greysquamae, dry and of small size, whereas the latter is characterized bygreasy, large and yellow squamae. The origin of this cutaneous drynesscan be of constitutional or acquired type.

In the case of constitutional dry skin, it is possible to distinguishtwo categories: pathologic skin and nonpathologic skin.

Pathologic constitutional dry skin is represented essentially by atopicdermatitis and ichthyoses. It is virtually independent of the externalconditions.

Atopic dermatitis is described as associated with a deficiency in themetabolism of the lipids of the stratum corneum and in particular of theceramides. This pathology presents itself in the form of a more or lesschronic xerosis affecting a large expanse of the body, associated or notassociated with inflammatory and pruriginous eruptions by patches.

Atopic dermatitides are also described as chronic inflammatorypathologies of the skin, often coexisting with other atopic pathologies,such as rhinitis, conjunctivitides and allergic asthma. In the majorityof cases, atopic dermatitis is reflected by dry skin associated withdysfunctionings of the epidermal barrier. An increase in imperceptiblewater loss is nearly always encountered.

Thus, the barrier function of the skin is detrimentally affected notonly on the parts affected by eczema but also with regard tononinflammatory dry skin. This detrimental change accordinglyfacilitates the penetration of various substances from the environmentinto the skin.

What is more, colonisation of the skin by Staphylococcus aureus strainsis generally correlated with atopic dermatitis.

Ichthyoses are pathologies characterized by a genetic deficiency whichaffects the keratinization process at various stages. They aremanifested by significant desquamation by patches.

The pathologic constitutional dry skin concerned according to thedisclosure is more particularly dry skin or dry scalp of noninflammatoryorigin.

In the case of nonpathologic constitutional dry skin, the severity ofthe state of dryness can, for its part, depend on external factors.Senile skin (characterized by a general reduction in cutaneousmetabolism with age), fragile skin (very sensitive to external factorsand often accompanied by erythema and rosacea) and xerosis vulgaris (ofprobable genetic origin and manifesting itself predominantly on theface, limbs and back of the hands) come within this skin category.

In the case of acquired dry skin, the involvement of externalparameters, such as exposure to chemical agents, to difficult climaticconditions, to solar radiation or alternatively certain therapeutictreatments (retinoids, for example), is determining. Under theseexternal influences, the epidermis can then become temporarily andlocally dry. This can concern any type of epidermis.

Thus, cutaneous dryness can also be induced by an exogenous stress ofchemical origin, for example of peeling type, or also of mechanicalorigin (rubbing, shaving).

It should be remembered that a peeling operation consists essentially inapplying a chemical substance to the skin with the aim of bringing aboutlimited and controlled destruction of the epidermis and of the surfacelayers of the dermis in order to improve certain disorders of theappearance of the skin.

At the same time as the peelings which may be described as chemical fromthe viewpoint of the chemical products which they employ, a technologyinvolving the use of ablative and nonablative laser beams has also beendeveloped.

The first ablative laser beams, produced with pulsed or scanned CO₂lasers, have the immediate effect of vaporizing (or ablating) theepidermis and often the upper part of the dermis. A strip of theunderlying dermis is generally also the site of thermal injury withdenaturation and contraction of the collagen. During the healing phase,reepithelization occurs starting from the hair follicles and otheradnexa in addition to an upper dermal strip (“remodelling of thecollagen”).

The latest generation of lasers uses a system of conversion of the laserbeam into a multitude of beams spaced out from one another in order toproduce, on the skin, impacts spaced out from one another, thusmaintaining, between the affected areas, areas of healthy skin notdetrimentally changed.

For obvious reasons, peeling thus has an action which, althoughcontrolled, remains irritating with regard to the surface of theepidermis and liable to induce cutaneous dryness.

The compositions, methods and uses according to the disclosure thusprove to be very particularly effective:

-   -   in treating states of cutaneous dryness, squamous states and in        particular dry dandruff states,    -   in treating dry skin,    -   in treating itching and/or tightness associated with dry skin,    -   in treating cutaneous disorders related to a deficiency in        excretion and/or secretion of sebum,    -   in physiologically restoring a suitable state of hydration to        the stratum corneum,    -   in treating hyposeborrhoeic dry skin,    -   in stimulating sebogenesis,    -   in preventing and/or reducing wrinkles related to cutaneous        dryness,    -   in improving the comfort of dry skin and a dry scalp, and in        particular dry dandruff states,    -   in combating the dull and/or lifeless appearance of the skin as        a consequence of it drying out,    -   in treating dry keratinous fibres,    -   in treating skin which has been subjected to a drying exogenous        stress induced by a chemical product, such as a peeling        composition, for example, or induced by peeling by radiation or        also induced mechanically, in particular by rubbing, for example        in shaving.

When the keratinous substances are human or animal keratinous fibres,such as the hair, body hairs and/or eyelashes, the active principleunder consideration according to the disclosure proves to beparticularly advantageous in preventing and/or treating the expressionof signs of weakness, such as, for example, the dryness which isgenerally reflected by a brittle aspect of the fibre. It thus makes itpossible to confer a glossy appearance on the keratinous fibres, inparticular on human hair and on the coats of animals.

According to one embodiment of the disclosure, a lysate ofmicroorganisms in accordance with the disclosure is not employed asagent for inhibiting adhesion of the pathogenic flora of the skin.

Microorganisms

As specified above, the microorganisms of the genus Bifidobacteriumspecies used as active principles according to the disclosure areemployed in the form of a lysate.

A lysate commonly denotes a material obtained on conclusion of thedestruction or dissolution of biological cells by a “cell lysis”phenomenon, thus resulting in the release of the intracellularbiological constituents naturally present in the cells of themicroorganism under consideration.

Within the meaning of the present disclosure, the term “lysate” is usedwithout distinction to denote the whole of the lysate obtained by lysisof the microorganism concerned or only a fraction of the latter.

The lysate employed is thus formed all or in part of the intracellularbiological constituents and of the wall and cell membrane constituents.

More specifically, it comprises the cell cytoplasmic fraction includingenzymes, such as lactic acid dehydrogenase, phosphatases,phosphoketolases and transaldolases. By way of illustration, theconstituents of the cell walls are in particular peptidoglycan, mureinor mucopeptide and teichoic acid and the constituents of the cellmembranes are compounds of glycerophospholipid.

This cell lysis can be accomplished by various technologies, such as,for example, osmotic shock, heat shock, with ultrasound, or also undermechanical stress of centrifuging type, for example.

More particularly, this lysate can be obtained according to technologydescribed in U.S. Pat. No. 4,464,362 and in particular according to thefollowing protocol.

The microorganism of Bifidobacterium species type under consideration iscultured anaerobically in an appropriate culture medium, for exampleaccording to the conditions described in the documents U.S. Pat. No.4,464,362 and EP 43 128. When the stationary phase of the development isreached, the culture medium can be inactivated by pasteurization, forexample at a temperature of 60 to 65° C. for 30 min. The microorganismsare then collected by a conventional separation technique, for examplemembrane filtration or centrifuging, and resuspended in a sterilephysiological NaCl solution.

The lysate can be obtained by disintegrating such a medium usingultrasound in order to release therefrom the cytoplasmic fractions, thecell wall fragments and the products resulting from the metabolism. Thenall the components in their natural distribution are subsequentlystabilized in a weakly acidic aqueous solution.

A concentration of the order of 0.1 to 50% by weight, in particular of 1to 20% by weight and especially of approximately 5% by weight of activematerial(s), with respect to the total weight of the lysate, is thusgenerally obtained.

The lysate can be employed in different forms, in the form of a solutionor in a pulverulent form.

The microorganism belonging to the genus Bifidobacterium species is moreparticularly chosen from the species: Bifidobacterium longum,Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacteriumanimalis, Bifidobacterium lactis, Bifidobacterium infantis,Bifidobacterium adolescentis or Bifidobacterium pseudocatenulatum andtheir mixtures.

The species Bifidobacterium longum is very particularly suitable for thedisclosure.

Within the meaning of the disclosure, the term “fraction” moreparticularly denotes a fragment of the said microorganism which iseffective in the treatment of dry epidermides by analogy with the saidwhole microorganism.

The product sold under the name Repair Complex CLR® by K. RICHTER GmbH,which is formed of an inactivated lysate of the species Bifidobacteriumlongum, comes within the scope of the disclosure.

The active principle forming the lysate belonging to the genusBifidobacterium species can be formulated in a proportion of at least0.0001% by weight (expressed as dry weight), in particular in aproportion of 0.001 to 20% by weight and more particularly in aproportion of 0.001 to 2% by weight, with respect to the total weight ofthe carrier or of the composition comprising it.

In the specific case where the microorganism(s) is (are) formulated incompositions to be administered by the oral route, the concentration ofmicroorganism(s), in particular probiotic microorganism(s), can beadjusted so as to correspond to doses (expressed as microorganismequivalent) varying from 5×10² to 10¹³ ufc/d and in particular from 10⁵to 10¹¹ ufc/d.

According to an alternative form of the disclosure, this lysate isemployed in combination with another microorganism.

Thus, the compositions according to the disclosure can in additionadvantageously comprise at least one additional microorganism, inparticular of probiotic type, and/or one of its fractions and/or one ofits metabolites.

Within the meaning of the present disclosure, the term “probioticmicroorganism” is understood to mean a living microorganism which, whenit is consumed in an appropriate amount, has a positive effect on thehealth of its host, “Joint FAO/WHO Expert Consultation on Evaluation ofHealth and Nutritional Properties of Probiotic in Food Including PowderMilk with Live Lactic Acid Bacteria, 6 Oct. 2001”, and which can inparticular improve the intestinal microbial balance.

These microorganisms which are suitable for the disclosure can be chosenin particular from the Ascomycetes, such as Saccharomyces, Yarrowia,Kluyveromyces, Torulaspora, Schizosaccharomyces pombe, Debaromyces,Candida, Pichia, Aspergillus and Penicillium, bacteria of the genusBacteroides, Fusobacterium, Melissococcus, Propionibacterium,Enterococcus, Lactococcus, Staphylococcus, Peptostreptococcus, Bacillus,Pediococcus, Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcusand Lactobacillus, and their mixtures.

Mention may in particular be made, as Ascomycetes which are particularlysuitable for the present disclosure, of Yarrowia lipolitica andKluyveromyces lactis, as well as Saccharomyces cerevisiae, Torulaspora,Schizosaccharamyces pombe, Candida and Pichia.

Specific examples of probiotic microorganisms are Lactobacillusacidophilus, Lactobacillus alimentarius, Lactobacillus curvatus,Lactobacillus delbruckii subsp. Lactis, Lactobacillus gasseri,Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus paracasei,Lactobacillus rhamnosus (Lactobacillus GG), Lactobacillus sake,Lactococcus lactis, Streptococcus thermophilus, Staphylococccuscarnosus, and Staphylococcus xylosus and their mixtures.

More particularly, they are probiotic microorganisms resulting from thegroup of the lactic bacteria, such as, in particular, the Lactobacillusspecies. Mention may more particularly be made, by way of illustrationof these lactic bacteria, of Lactobacillus johnsonii, Lactobacillusparacasei, Lactobacillus reuteri, Lactobacillus rhamnosus and theirmixtures.

As specified above, the additional microorganism may or may not be thesame species as that forming the lysate. However, when it is the samespecies, it is then present in a form other than a lysate, for examplein a living form.

The species which are very particularly suitable are Lactobacillusjohnsonii, in particular the strain deposited according to the Treaty ofBudapest with the Institut Pasteur (28 rue du Docteur Roux, F-75024Paris cedex 15) under the following designation CNCM I-1225.

Generally, the compositions for topical application according to thedisclosure generally comprise from 0.0001 to 30%, in particular from0.001 to 15% and more particularly from 0.1 to 10% of one or moreadditional microorganisms, in particular probiotic microorganisms.

This or these microorganism(s) can be included in the compositionsaccording to the disclosure in a living, semi-active or inactivated, ordead form.

It/they can also be included in the form of fractions of cellcomponents. The microorganism(s) or fraction(s) can also be introducedin the form of a powder, of a liquid, of a culture supernatant or one ofits fractions, diluted or undiluted, or also concentrated ornonconcentrated.

In the case where the microorganisms are formulated in a composition ina living form, the amount of living microorganisms can vary from 10³ to10¹⁵ ufc/g, in particular from 10⁵ to 10¹⁵ ufc/g and more particularlyfrom 10⁷ to 10¹² ufc/g of microorganisms per gram of composition.

The compositions according to the disclosure can be provided in all theformulation forms normally available for the method of administrationselected.

The carrier can be of various natures, depending on the type ofcomposition under consideration.

As regards more particularly the compositions intended foradministration by the external topical route, that is to say at thesurface of a keratinous substance, such as the skin, they can beaqueous, aqueous/alcoholic or oily solutions, dispersions of the type ofsolutions or dispersions of the lotion or serum type, emulsions of aliquid or semi-liquid consistency of the milk type, obtained bydispersion of a fatty phase in an aqueous phase (O/W) or vice versa(W/O), or of suspensions or emulsions of the cream type, aqueous oranhydrous gels, microemulsions, microcapsules, microparticles orvesicular dispersions of ionic and/or nonionic type.

These compositions are prepared according to the usual methods.

These compositions can in particular constitute cleansing, protecting,treating or care creams for the face, for the hands, for the feet, forthe major anatomical folds or for the body (for example, day creams,night creams, make-up-removing creams, cream foundations or sun creams),make-up products, such as liquid foundations, make-up-removing milks,protective or care body milks, aftersun milks, lotions, gels or foamsfor caring for the skin, such as cleansing or disinfecting lotions, sunlotions, artificial tanning lotions, bath compositions, deodorantcompositions comprising a bactericidal agent, aftershave gels orlotions, depilatory creams or compositions for combating insect stingsand bites.

The compositions according to the disclosure can also consist of solidpreparations constituting cleansing soaps or bars.

They can also be used for the scalp in the form of solutions, creams,gels, emulsions or foams or also in the form of aerosol compositionsalso comprising a pressurized propellant.

When the composition of the disclosure is an emulsion, the proportion ofthe fatty phase can range from 5 to 80% by weight and preferably from 5to 50% by weight, with respect to the total weight of the composition.The oils, the emulsifiers and the coemulsifiers used in the compositionin the form of an emulsion are chosen from those conventionally used inthe cosmetic and/or dermatological field. The emulsifier and thecoemulsifier can be present in the composition in a proportion rangingfrom 0.3 to 30% by weight and preferably from 0.5 to 20% by weight, withrespect to the total weight of the composition.

When the composition of the disclosure is an oily solution or gel, thefatty phase can represent more than 90% of the total weight of thecomposition.

In a known way, the formulation forms intended for topicaladministration can also comprise adjuvants which are normal in thecosmetic, pharmaceutical and/or dermatological field, such ashydrophilic or lipophilic gelling agents, hydrophilic or lipophilicactive principles, preservatives, antioxidants, solvents, fragrances,fillers, screening agents, bactericides, odour absorbers and colouringmaterials. The amounts of these various adjuvants are thoseconventionally used in the field under consideration, for example from0.01 to 20% of the total weight of the composition. These adjuvants,depending on their nature, can be introduced into the fatty phase and/orinto the aqueous phase.

Mention may be made, as fatty substances which can be used in thedisclosure, of mineral oils, such as, for example, hydrogenatedpolyisobutene and liquid petrolatum, vegetable oils, such as, forexample, a liquid fraction of shea butter, sunflower oil and apricotkernel oil, animal oils, such as, for example, perhydrosqualene,synthetic oils, in particular Purcellin oil, isopropyl myristate andethylhexyl palmitate, unsaturated fatty acids and fluorinated oils, suchas, for example, perfluoropolyethers. Use may also be made of fattyalcohols, fatty acids, such as, for example, stearic acid, and such as,for example, waxes, in particular paraffin wax, carnauba wax andbeeswax. Use may also be made of silicone compounds, such as siliconeoils, for example cyclomethicones and dimethicones, silicone waxes,silicone resins and silicone gums.

Mention may be made, as emulsifiers which can be used in the disclosure,for example, of glyceryl stearate, polysorbate 60, the cetearylalcohol/oxyethylenated cetearyl alcohol comprising 33 mol of ethyleneoxide mixture sold under the name Sinnowax AO™ by Henkel, thePEG-6/PEG-32/Glycol Stearate mixture sold under the name Tefose® 63 byGattefossé, PPG-3 myristyl ether, silicone emulsifiers, such as cetyldimethicone copolyol, and sorbitan mono- or tristearate, PEG-40 stearateor oxyethylenated (20 EO) sorbitan monostearate.

Mention may be made, as solvents which can be used in the disclosure, oflower alcohols, in particular ethanol and isopropanol, or propyleneglycol.

The composition of the disclosure can also advantageously comprise athermal and/or mineral water chosen in particular from water fromVittel, water from the Vichy basin and water from La Roche Posay.

Mention may be made, as hydrophilic gelling agents, of carboxylpolymers, such as carbomer, acrylic copolymers, such asacrylate/alkylacrylate copolymers, polyacrylamides, in particular themixture of polyacrylamide, C13-14 Isoparaffin and Laureth-7 sold underthe name Sepigel 305™ by SEPPIC, polysaccharides, such as cellulosederivatives, for example hydroxyalkylcelluloses, in particularhydroxypropylcellulose and hydroxyethylcellulose, natural gums, such asguar, locust bean and xanthan gums, and clays.

Mention may be made, as lipophilic gelling agents, of modified clays,such as bentones, metal salts of fatty acids, such as aluminiumstearates, and hydrophobic silica, or also ethylcellulose andpolyethylene.

In the case of the use of a combination in accordance with thedisclosure by the oral route, use of an ingestible carrier is favoured.

Milk, yogurt, cheese, fermented milks, milk-based fermented products,ice creams, products based on fermented cereals, milk-based powders,formulas for children and infants, foodstuffs of confectionery,chocolate or cereal type, foods for animals, in particular domesticanimals, tablets, including compressed tablets, hard gelatin capsules,oral supplements in a dry form and oral supplements in the liquid formare suitable in particular as dietary or pharmaceutical carriers.

Numerous embodiments of oral compositions and in particular of foodsupplements are possible for ingestion. They are formulated by standardprocesses for producing tablets, including sugar-coated tablets,capsules, including hard gelatin capsules, gels or emulsions. Inparticular, the active principle(s) according to the disclosure can beincorporated in any other form of food supplement or enriched food, forexample food bars, or compacted or uncompacted powders. The powders canbe diluted with water or in fizzy drinks, dairy products or soyaderivatives or can be incorporated in food bars.

According to a specific embodiment, the additional microorganisms underconsideration according to the disclosure can be formulated incompositions in an encapsulated form, so as to significantly improvetheir lifetime. In such a case, the presence of a capsule can inparticular slow down or prevent the decomposition of the microorganismin the gastrointestinal tract.

Of course, the topical or oral compositions or the combinationsaccording to the disclosure can additionally comprise several otheractive principles.

Mention may be made, as active principles conventionally employed, ofvitamins B3, B5, B6, B8, C, E or PP, niacin, carotenoids, polyphenolsand minerals, such as zinc, calcium, magnesium, and the like.

In particular, use may be made of an antioxidant complex comprisingvitamins C and E and at least one carotenoid, in particular a carotenoidchosen from β-carotene, lycopene, astaxanthin, zeaxanthin and lutein,flavonoids, such as catechins, hesperidin, proanthocyanidins andanthocyanins.

At least one prebiotic or one mixture of prebiotics may also beinvolved. More particularly, these prebiotics can be chosen fromoligosaccharides, produced from glucose, galactose, xylose, maltose,sucrose, lactose, starch, xylan, hemicellulose, inulin, gums of acaciatype, for example, or one of their mixtures. More particularly, theoligosaccharide comprises at least one fructooligosaccharide. Moreparticularly, this prebiotic can comprise a mixture offructooligosaccharide and of inulin.

In the topical formulation forms, use may more particularly be made, ashydrophilic active principles, of proteins or protein hydrolysates,amino acids, polyols, in particular C₂ to C₁₀ polyols, such as glycerol,sorbitol, butylene glycol and polyethylene glycol, urea, allantoin,sugars and sugar derivatives, water-soluble vitamins, starch, orbacterial or plant extracts, such as those of aloe vera.

As regards the lipophilic active principles, use may be made of retinol(vitamin A) and its derivatives, tocopherol (vitamin E) and itsderivatives, ceramides, essential oils and nonsaponifiable materials(tocotrienol, sesamin, γ-oryzanol, phytosterols, squalenes, waxes orterpenes).

According to one embodiment, a composition of the disclosure is devoidof vitamin A.

According to an alternative form of the disclosure, the lysate inaccordance with the disclosure can be employed in a topical compositionwith an agent which is active with regard to the epidermides, inparticular dry epidermides.

Mention may in particular be made, by way of illustration and withoutimplied limitation of such active principles, of moisturizing activeprinciples.

The term “moisturizing active principle” is understood to mean:

-   -   either a compound which influences the barrier function, for the        purpose of maintaining the hydration of the stratum corneum, or        an occlusive compound. Mention may be made of ceramides,        sphingoid-based compounds, lecithins, glycosphingolipids,        phospholipids, cholesterol and its derivatives, phytosterols        (stigmasterol, β-sitosterol or campesterol), essential fatty        acids, 1-2-diacylglycerol, 4-chromanone, pentacyclic        triterpenes, petrolatum and lanolin;    -   or a compound which directly increases the water content of the        stratum corneum, such as urea and its derivatives, trehalose and        its derivatives, hyaluronic acid and its derivatives, glycerol,        pentanediol, pidolates, serine, xylitol, lactic acid and sodium        lactate, glyceryl polyacrylate, ectoine and its derivatives,        chitosan, oligo- and polysaccharides, cyclic carbonates,        N-lauroylpyrrolidonecarboxylic acid and N-α-benzoyl-L-arginine;    -   or a compound which activates the sebaceous glands, such as        steroidal derivatives (including DHEA) and vitamin D and its        derivatives.

These compounds can represent from 0.001% to 30% and preferably from0.01 to 20% of the total weight of the composition according to thedisclosure.

Mention may more particularly be made, by way of illustration of theurea derivatives, of the (hydroxyalkyl)urea derivatives, in particularderivatives described in the document FR 2 877 222.

Consideration may also be given, as active principles capable of beingmore particularly combined with the lysate in an oral formulationformula, to all the ingredients commonly used and/or authorized.

Mention may be made, by way of illustration, of vitamins, minerals,essential lipids, trace elements, polyphenols, flavonoids,phyto-oestrogens, antioxidants, such as lipoic acid and coenzyme Q10,carotenoids, prebiotics, proteins and amino acids, mono- andpolysaccharides, amino sugars, phytosterols and triterpene alcohols ofplant origin.

They are in particular vitamins A, C, D, E, PP and of the group B. Thechoice has preferably been made, among carotenoids, of β-carotene,lycopene, lutein, zeazanthin and astaxanthin. The minerals and traceelements particularly employed are zinc, calcium, magnesium, copper,iron, iodine, manganese, selenium or chromium(III). The selection isalso in particular made, among polyphenols, of grape, tea, olive, cocoa,coffee, potato, blueberry, elder, strawberry, cranberry and onionpolyphenols. The selection is preferably made, among phyto-oestrogens,of isoflavones in the free or glycosylated form, such as genistein,daidzein or glycitein, or lignans, in particular those of flax andSchisandra chinensis. Amino acids or the peptides and the proteinscomprising them, such as taurine, threonine, cysteine, tryptophan ormethionine. The lipids preferably belong to the group of the oilscomprising mono- and polyunsaturated fatty acids, such as oleic,linoleic, α-linolenic, γ-linolenic or stearidonic acids, long-chain fishω-3 fatty acids, such as EPA and DHA, or conjugated fatty acidsresulting from plant or animals, such as CLAs (Conjugated LinoleicAcid).

The cosmetic treatment method of the disclosure can be employed inparticular by administering the cosmetic and/or dermatologicalcompositions or the combinations as defined above according to the usualtechnique for the use of these compositions. For example: applicationsof creams, gels, serums, lotions, make-up-removing milks or aftersuncompositions to the keratinous substance, such as dry skin or hair, orapplication of a hair lotion to wet hair or of shampoos as regards thetopical application.

The cosmetic method according to the disclosure can thus be employed bytopical administration, for example daily, of the lysate underconsideration according to the disclosure.

The method according to the disclosure can comprise a singleadministration. According to another embodiment, the administration isrepeated, for example 2 to 3 times daily over a day or more andgenerally over a prolonged period of time of at least 4 weeks, indeedeven 4 to 15 weeks, with, if appropriate, one or more periods ofinterruption.

In the description and in the following examples, unless otherwiseindicated, the percentages are percentages by weight and the ranges ofvalues worded in the form “between . . . and . . . ” include the lowerand upper limits specified. The ingredients are mixed, before they areformed, in the order and under conditions easily determined by a personskilled in the art.

The following examples are presented by way of illustration and withoutimplied limitation of the field of the disclosure.

Example 1

Milk for the care of dry skin of the face % by weight Magnesium chloride3.00 Calcium ascorbate 3.00 Bifidobacterium longum 10.00** lysate CLR(Repair Complex CLR ®)* Glyceryl stearate 1.00 Cetearylalcohol/oxyethylenated cetearyl alcohol 3.00 comprising 30 mol of EO(Sinnowax AO ®, sold by Henkel) Cetyl alcohol 1.00 Dimethicone (DC 200Fluid ® sold by Dow Corning) 1.00 Liquid petrolatum 6.00 Isopropylmyristate (Estol IMP 1514 ®, sold by Uniqema) 3.00 Antioxidant 0.05Glycerol 20.00 Preservative 0.30 Water q.s. for 100 *Repair ComplexCLR ®, sold by K. Richter GmbH and corresponding to a formulationcomprising 5% by weight of active principles **amount expressed as totalproduct

Example 2

Milk for the care of dry skin of the face % by weight Magnesiumascorbate 3.00 Blackcurrant seed oil 4.00 Borage oil 4.00 InactivatedLactobacillus johnsonii powder 5.00 Bifidobacterium longum lysate CLR10.00** (Repair Complex CLR ®)* Glyceryl stearate 1.00 Cetearylalcohol/oxyethylenated cetearyl alcohol 3.00 comprising 3 mol of EO(Sinnowax AO ®, sold by Henkel) Cetyl alcohol 1.00 Dimethicone (DC 200Fluid ®, sold by Dow Corning) 1.00 Liquid petrolatum 6.00 Isopropylmyristate (Estol IPM 1514 ®, sold by Uniqema) 3.00 Glycerol 20.00Preservative 0.30 Water q.s. for 100 *Repair Complex CLR ®, sold by K.Richter GmbH and corresponding to a formulation comprising 5% by weightof active principles **amount expressed as total product

Example 3

Lotion for the scalp % by weight Bifidobacterium longum lysate CLR5.00** (Repair Complex CLR ®)* Antioxidant 0.05 Isopropanol 40.0Preservative 0.30 Water q.s for 100 *Repair Complex CLR ® sold by K.Richter GmbH and corresponding to a formulation comprising 5% by weightof active principles **amount expressed as total product

Example 4

Milk for the care of the scalp % by weight Bifidobacterium longum(lysate CLR) 5.00** (Repair Complex CLR ®)* Glyceryl stearate 1.00Cetearyl alcohol/oxyethylenated cetearyl alcohol 3.00 comprising 30 molof EO (Sinnowax AO ®, sold by Henkel) Cetyl alcohol 1.00 Dimethicone (DC200 Fluid ® sold by Dow Corning) 1.00 Liquid petrolatum 6.00 Isopropylmyristate (Estol IMP 1514 ®, sold by Uniqema) 3.00 Antioxidant 0.05Preservative 0.30 Water q.s. for 100 *Repair Complex CLR ® sold by K.Richter GmbH and corresponding to a formulation comprising 5% by weightof active principles **amount expressed as total product

Example 5

Gel for the care of the scalp % by weight Bifidobacterium longum (lysateCLR) 5.00** (Repair Complex CLR ®)* Hydroxypropylcellulose (Klucel H ®,sold by Hercules) 1.00 Vitamin E 2.50 Antioxidant 0.05 Isopropanol 40.00Preservative 0.30 Water q.s. for 100 *Repair Complex CLR ® sold by K.Richter GmbH and corresponding to a formulation comprising 5% by weightof active principles **amount expressed as total product

Example 6

Cream for the care of the scalp % by weight Arachidyl behenylalcohol/arachidyl glucoside 3.0 Isohexadecane 7.0 Bifidobacterium longum(lysate CLR) 5.00** (Repair Complex CLR ®)* Glycerol 2.0 Vitreoscillafiliformis extract 3.0 BHT 0.05 Methyl POB 0.1 Propyl POB 0.05 Waterq.s. for 100 *Repair Complex CLR ® sold by K. Richter GmbH andcorresponding to a formulation comprising 5% by weight of activeprinciples **amount expressed as total product

Example 7

Gel for the care of the hair % by weight Bifidobacterium longum (lysateCLR) 5.00** (Repair Complex CLR ®)* Copper citrate 2.00 Vitreoscillafiliformis extract 3.00 Antioxidant 0.05 Vitamin C 2.50 Antioxidant 0.05Isopropanol 40.00 Preservative 0.30 Water q.s. for 100 *Repair ComplexCLR ® sold by K. Richter GmbH and corresponding to a formulationcomprising 5% by weight of active principles **amount expressed as totalproduct

Example 8

Lotion for the face % by weight Bifidobacterium longum lysate (RepairComplex CLR ®)* 5.00** Antiinflammatory 0.05 Antioxidant 0.05Isopropanol 40.0 Preservative 0.30 Water q.s. for 100 *Repair ComplexCLR ® sold by K. Richter GmbH and corresponding to a formulationcomprising 5% by weight of active principles **amount expressed as totalproduct

Example 9

Gel for the care of the face % by weight Bifidobacterium longum lysate(Repair Complex CLR ®)* 5.00** Hydroxypropylcellulose (Klucel H ®, soldby Hercules) 1.00 Vitamin E 2.50 Antioxidant 0.05 Isopropanol 40.00Preservative 0.30 Water q.s. for 100 *Repair Complex CLR ® sold by K.Richter GmbH and corresponding to a formulation comprising 5% by weightof active principles **amount expressed as total product

Example 10

Cream for the care of the face % by weight Arachidyl behenylalcohol/arachidyl glucoside 3.0 Isohexadecane 7.0 Bifidobacterium longumlysate (Repair Complex CLR ®)* 5.00** Glycerol 2.0 Vitreoscillafiliformis extract 3.0 BHT 0.05 Methyl POB 0.1 Propyl POB 0.05 Waterq.s. for 100 *Repair Complex CLR ® sold by K. Richter GmbH andcorresponding to a formulation comprising 5% by weight of activeprinciples **amount expressed as total product

Example 11

Gel for the care of the face % by weight Vitreoscilla filiformis extract3.00 Bifidobacterium longum lysate (Repair Complex CLR ®)* 5.00**Antioxidant 0.05 Vitamin C 2.50 Antioxidant 0.05 Isopropanol 40.00Preservative 0.30 Water q.s. for 100 *Repair Complex CLR ® sold by K.Richter GmbH and corresponding to a formulation comprising 5% by weightof active principles **amount expressed as total product

Example 12 Evaluation of the Dryness of Subjects Treated with aBifidobacterium Lysate

The product tested is a Bifidobacterium longum lysate in disintegrated(with ultrasound) suspension in a weakly acidic aqueous medium, soldunder the name Repair Complex CLR®.

The active principle was tested alone in a randomized double blindstudy.

Sixty-six women exhibiting dry skin were divided into two groups,placebo (n=33, group A), Repair Complex CLR® (n=33 group B). Thetreatments were applied topically for 58 days, the active principlebeing formulated at 10% of the test formulation. This carrierformulation is an Arlacel/myrj® oil/demineralized water emulsioncomprising 5% Parleam, 15% cyclopentasiloxane, 3% glycerol and 2%petrolatum.

In the placebo formulation, the absence of Repair Complex CLR® iscompensated for with water.

The subjects were evaluated at D1, D29, D43 and D57. On each visit,evaluations of the dryness of the legs were carried out by thedermatologist and by self-evaluation by the subjects according to theforms specified below.

The investigating dermatologist evaluated on each visit the cutaneousdryness of the area studied (the external face of the right leg)according to a squama from 0 to 3 with regard to the following criteria:0=skin not dry, 1=slight dryness (slight roughness), 2=moderate dryness(moderate roughness, a few squamas), 3=severe dryness (significantroughness and desquamation).

Furthermore, the investigating dermatologist, on each visit, asked thesubject for a self-evaluation of the state of cutaneous dryness of herlegs according to the following squama from 0 to 5: 0=not at all; 1=veryslightly; 2=slightly; 3=moderately; 4=strongly; 5=very strongly.

At the same time, the change in various cutaneous markers was studied byproteomics.

A sample is withdrawn from the external face of the leg at times D1,D29, D43 and D57 by varnish stripping in order to withdraw only aportion of the stratum corneum, i.e. at most 4 to 5 layers of stratumcorneum.

A 41 μm filter, type NY41 Millipore, nylon cloth (5×5 cm) is applied toa predefined area of the left leg. A transparent varnish with reference614254/T.D., comprising: nitrocellulose 6.86 g; isopropanol 2.94 g;hypoallergenic alkyl resin 7.35 g; tributyl acetylcitrate 7.7 g; ethylacetate 75.15 g; is then spread using a brush (15 mm) and then left todry for 15 min. The nylon cloth is subsequently recovered usingtweezers, the varnish strip being torn off with a sharp movement.

The varnish strips are stored flat at −20° C. in plastic bags.

These withdrawn samples of skin (stratum corneum varnish strips) weresubsequently analysed by proteomics in order to evaluate the expressionof various proteins according to the method described by Zieske (J. Exp.Bot., 2006, 547:1501) and Wiesse et al., (Proteomics, 2007, 7:340).

Results

a) By Clinical Scoring

The forms of the score of cutaneous dryness, expressed as percentage,per visit and treatment are represented in Table 1 below. The groups arecomparable at day 1 (p=0.8677).

An improvement over time is observed in both groups, which improvementis more marked for the group being treated with the topical formulationcomprising 10% of Repair Complex CLR® and very particularly at D29.

TABLE 1 Clinical Legs 0 1 2 3 Total A Time D1 Participants 0 0 21 11 32% over time .0% .0% 65.6% 34.4% 100.0% D15 Participants 7 8 15 2 32 %over time 21.9% 25.0% 46.9% 6.3% 100.0% D29 Participants 4 18 7 1 30 %over time 13.3% 60.0% 23.3% 3.3% 100.0% D43 Participants 8 15 3 3 29 %over time 27.6% 51.7% 10.3% 10.3% 100.0% D57 Participants 13 10 4 1 28 %over time 46.4% 35.7% 14.3% 3.6% 100.0% Total Participants 32 51 50 18151 % over time 21.2% 33.8% 33.1% 11.9% 100.0% B Time D1 Participants 00 21 10 31 % over time .0% .0% 67.7% 32.3% 100.0% D15 Participants 5 169 0 30 % over time 16.7% 53.3% 30.0% .0% 100.0% DJ29 Participants 8 19 30 30 % over time 26.7% 63.3% 10.0% .0% 100.0% D43 Participants 3 24 2 130 % over time 10.0% 80.0% 6.7% 3.3% 100.0% D57 Participants 11 15 4 030 % over time 36.7% 50.0% 13.3% .0% 100.0% Total Participants 27 74 3911 151 % over time 17.9% 49.0% 25.8% 7.3% 100.0%

The reduction in the clinical score for dryness over time appears to bevery significant (Chi-Square test, p<0.0001). Thus, a significantdifference is observed between the groups at D29 (one-sided Chi-squaretest; p=0.0612) in favour of the treatment with the topical formulationcomprising 10% of Repair Complex CLR®.

b) By Self-Evaluation

The forms of the score for self-evaluated cutaneous dryness, expressedas percentage, per visit and treatment are represented in Table 2 below.The groups are comparable at D1 (p=0.3945).

An improvement over time is observed in both groups, which improvementproves to be more marked for the group treated with the topicalformulation comprising 10% of Repair Complex CLR®, particularly at D29,in a way comparable to what had been observed for the clinical score.

TABLE 2 Legs rando 0 1 2 3 4 5 Total A Time D1 Participants 0 0 2 9 15 632 % over time .0% .0% 6.3% 28.1% 46.9% 18.8% 100.0% D15 Participants 211 6 11 2 0 32 % over time 6.3% 3.4% 18.8% 34.4% 6.3% .0% 100.0% D29Participants 4 6 9 11 0 0 30 % over time 13.3% 20.0% 30.0% 36.7% .0% .0%100.0% D43 Participants 5 9 9 5 1 0 29 % over time 17.2% 31.0% 31.0%17.2% 3.4% .0% 100.0% D57 Participants 6 7 9 5 1 0 28 % over time 21.4%25.0% 32.1% 17.9% 3.6% .0% 100.0% Total Participants 17 33 35 41 19 6151 % over time 11.3% 21.9% 23.2% 27.2% 12.6% 4.0% 100.0% B Time D1Participants 0 0 5 10 9 7 31 % over time .0% .0% 16.1% 32.3% 29.0% 22.6%100.0% D15 Participants 6 5 10 6 3 0 30 % over time 20.0% 16.7% 33.3%20.0% 10.0% .0% 100.0% D29 Participants 8 9 7 5 1 0 30 % over time 26.7%30.0% 23.3% 16.7% 3.3% .0% 100.0% D43 Participants 6 13 8 3 0 0 30 %over time 20.0% 43.3% 26.7% 10.0% .0% .0% 100.0% D57 Participants 8 14 53 0 0 30 % over time 26.7% 46.7% 16.7% 10.0% .0% .0% 100.0% TotalParticipants 28 41 35 27 13 7 151 % over time 18.5% 27.2% 23.2% 17.9%8.6% 4.6% 100.0%

The groups were compared on the different visits. A significantdifference is observed between the groups at D29 (one-sided Chi-squaretest; p=0.0561) in favour of the group treated with the topicalformulation comprising 10% of Repair Complex CLR®.

c) Analysis by Proteomics

The results of the analysis by proteomics showed that theBifidobacterium longum lysate stimulates the expression of variousproteins which defend the epidermis from microorganisms such as theRNase 7, the dermcidin, the prolactin inducible protein (PiP), theproteins S100 A8 and A9, the histone protein of certain proteasesinvolved in the phenomenon of desquamation (KLK7, KLK5, Cathepsin L2),while other proteins reflecting the metabolic immatunity of thecutaneous barrier see the decrease of their expression (Bleomycinhydrolase, Enolase 1, TP1, GAPDH).

The defense properties of the skin against dryness are thereforestrengthened.

CONCLUSION

For the dryness of the legs (both by the clinical study and theself-evaluations), a significant reduction is observed at D29 and,overall, after 2 months, a tendency towards reduction is observed forthe subjects who have been treated with the topical formulationcomprising 10% of Repair Complex CLR®.

Although the present disclosure herein has been described with referenceto particular embodiments, it is to be understood that these embodimentsare merely illustrative of the principles and applications of thepresent disclosure. It is therefore to be understood that numerousmodifications may be made to the illustrative embodiments and that otherarrangements may be devised without departing from the spirit and scopeof the present disclosure as defined by the appended claims.

1. A cosmetic method for treating and/or preventing dryness and/orassociated disorders of a keratinous substance comprising administeringto a subject an effective amount of a lysate of at least onemicroorganism of the genus Bifidobacterium species and/or one of itsfractions.
 2. The method according to claim 1, in which the saidmicroorganism is intended to prevent or treat dry skin.
 3. The methodaccording to claim 1, in which the said microorganism is intended toprevent and/or reduce the wrinkles related to cutaneous dryness.
 4. Themethod according to claim 1, in which the said microorganism is intendedto improve the comfort of dry skin and a dry scalp.
 5. The methodaccording to claim 1, in which the said microorganism is intended tocombat the dull and/or lifeless appearance of the skin as a consequenceof it drying out.
 6. The method according to claim 1, in which the saidmicroorganism is intended to prevent and/or treat drying of the skin asa consequence of an application of a chemical product and/or thecarrying out of a peeling or of a shaving operation.
 7. The methodaccording to claim 1, in which the said microorganism is intended toprevent or treat the expression of signs of weakness of keratinousfibres.
 8. The method according to claim 1, in which the microorganismof the genus Bifidobacterium species is selected from the groupconsisting of Bifidobacterium longum, Bifidobacterium bifidum,Bifidobacterium breve, Bifidobacterium animalis, Bifidobacterium lactis,Bifidobacterium infantis, Bifidobacterium adolescentis orBifidobacterium pseudocatenulatum and their mixtures.
 9. The methodaccording to claim 1, in which the microorganism of the genusBifidobacterium species is Bifidobacterium longum.
 10. The methodaccording to claim 1, in which the said lysate comprises from 0.1 to 50%by weight, of active material(s).
 11. The method according to claim 1,in which the said lysate is administered by the topical route.
 12. Themethod according to claim 1, in which the said lysate is administered bythe oral route.
 13. A cosmetic method for treating and/or preventing adry dandruff state of the scalp comprising administering to a subject aneffective amount of a lysate of at least one microorganism of the genusBifidobacterium species and/or one of its fractions.
 14. A method fortreating and/or preventing dryness or associated disorders of akeratinous substance comprising the preparation of a compositioncomprising an effective amount of a lysate of at least one microorganismof the genus Bifidobacterium species and/or one of its fractions.
 15. Amethod for treating and/or preventing a dry dandruff state of the scalpcomprising the preparation of a composition comprising an effectiveamount of a lysate of at least one microorganism of the genusBifidobacterium species and/or one of its fractions.
 16. A cosmeticand/or dermatological composition for preventing and/or treating drykeratinous substances, comprising, in a physiologically acceptablemedium, at least an effective amount of a lysate of at least onemicroorganism of the genus Bifidobacterium species in combination withat least an effective amount of at least one additional microorganism,and/or one of its fractions and/or one of its metabolites, distinct fromthe said lysate.
 17. The composition according to claim 16, in which themicroorganism of the genus Bifidobacterium species is selected from thegroup consisting of Bifidobacterium longum, Bifidobacterium bifidum,Bifidobacterium breve, Bifidobacterium animalis, Bifidobacterium lactis,Bifidobacterium infantis, Bifidobacterium adolescentis orBifidobacterium pseudocatenulatum, and their mixtures.
 18. Thecomposition according to claim 16, in which the said lysate is presentin a proportion of at least one 0.0001% by weight (expressed as dryweight) with respect to the total weight of the said composition. 19.The composition according to claim 16, in which the said probioticmicroorganism is selected from the group consisting of the Ascomycetes,such as Saccharomyces, Yarrowia, Kluyveromyces, Torulaspora,Schizosaccharomyces pombe, Debaromyces, Candida, Pichia, Aspergillus andPenicillium, bacteria of the genus Bifidobacterium, Bacteroides,Fusobacterium, Melissococcus, Propionibacterium, Enterococcus,Lactococcus, Staphylococcus, Peptostreptococcus, Bacillus, Pediococcus,Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcus,Lactobacillus, and their mixtures.
 20. The composition according toclaim 16, in which the additional microorganism results from the groupof the lactic bacteria.
 21. The composition according to claim 16, inwhich the additional microorganism is chosen from the strainsLactobacillus johnsonii (CNCM I-1225).
 22. The composition according toclaim 16, in which the probiotic microorganism and/or one of itsfractions and/or one of its metabolites is present in a proportion of0.1 to 10% by weight of the said composition.
 23. The compositionaccording to claim 16, in which it is provided in the form of aqueous,aqueous/alcoholic or oily solutions, of dispersions of the type ofsolutions or dispersions of the lotion or serum type, of emulsions ofthe liquid or semiliquid consistency of the milk type, obtained bydispersion of a fatty phase in an aqueous phase (O/W) or vice versa(W/O), or of suspensions or emulsions with a soft, semisolid or solidconsistency of the cream type, of aqueous or anhydrous gels, or also ofmicroemulsions, of microcapsules, of microparticles or of vesiculardispersions of anionic and/or nonionic type.
 24. A cosmetic and/ordermatological composition, of use in particular for preventing and/ortreating dry keratinous substances, comprising, in a physiologicallyacceptable medium, at least an effective amount of a lysate of at leastone microorganism of the genus Bifidobacterium species in combinationwith at least an effective amount of at least one moisturizing activeprinciple.
 25. A cosmetic method for treating and/or preventing drynessand/or associated disorders of a keratinous substance in a subject,comprising at least one step of administration to the said subject of atleast an effective amount of at least one microorganism of the genusBifidobacterium species in the form of a lysate.
 26. The methodaccording to claim 25, in which the microorganism of the genusBifidobacterium species is selected from the group consisting ofBifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium breve,Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacteriuminfantis, Bifidobacterium adolescentis or Bifidobacteriumpseudocatenulatum and their mixtures.